Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
100%(7 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
5
71%
Ph phase_3
1
14%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
Phase 31 (14.3%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Tecemotide (L-BLP25) in Prostate Cancer

NCT01496131
completedphase_2

Tecemotide (L-BLP25) in Rectal Cancer

NCT01507103
completedphase_2

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

NCT01094548
completedphase_3

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

NCT00409188
completedphase_2

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

NCT00157209
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01496131Phase 2

Tecemotide (L-BLP25) in Prostate Cancer

Completed
NCT01507103Phase 2

Tecemotide (L-BLP25) in Rectal Cancer

Completed
NCT01094548Phase 2

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

Completed
NCT00409188Phase 3

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

Completed
NCT00157209Phase 2

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Completed
NCT00960115Phase 1

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Completed
NCT00157196Phase 2

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7